Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: A correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model.

This study was carried out to determine the effect of recombinant human bone morphogenetic protein (rhBMP) pharmacokinetics (PK) on rhBMP-induced osteoinductive activity. It was our working hypothesis that the PK of a rhBMP significantly affects its osteoinductive activity. The PK of various rhBMPs (rhBMP-2, rhBMP-4, rhBMP-6, and chemically modified rhBMP-2) implanted with four biomaterial carries (Helistat, hDBM, Osteograf/N, and Dexon) was determined using (125)I-labeled proteins in the rat ectopic assay. A select combination of rhBMP and carriers then was evaluated in the rat ectopic assay for osteoinductive activity using a semi-quantitative histologic scoring system. The results indicate that initial protein retention is dependent on protein isoelectric point (pI); proteins with a higher pI yielded a higher implant retention. Subsequent PK was not strongly dependent on the pI or on the carrier. Because of the difference in early retention, the rhBMP-carrier combinations exhibited a >100-fold difference in implant-retained protein dose. When rhBMP-2 and rhBMP-4 were implanted with the carriers, more rhBMP-2 was retained in an implant, and the osteoinductive potency of rhBMP-2 typically was higher than rhBMP-4 at low implantation doses. We conclude that protein pI plays a significant role in the local retention of implanted rhBMP and that higher retention yields a higher osteoinductive activity.

[1]  R. Kaufman,et al.  Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. , 1992, Growth factors.

[2]  C. Goochee,et al.  Removal of Sialic Acid from a Glycoprotein in CHO Cell Culture Supernatant by Action of an Extracellular CHO Cell Sialidase , 1995, Bio/Technology.

[3]  K. Leong,et al.  Poly(α-hydroxy acids). Carriers for bone morphogenetic proteins , 1996 .

[4]  F. Hughes,et al.  The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. , 1995, Endocrinology.

[5]  D. Hauschke,et al.  International Harmonization of Regulatory Bioequivalence Requirements , 1993 .

[6]  V. Rosen,et al.  Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  J. Wozney,et al.  Biotinated bone morphogenetic protein-2: In vivo and in vitro activity. , 1999, Biotechnology and bioengineering.

[8]  J. Wozney,et al.  Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro. , 1996, Endocrinology.

[9]  V. Rosen,et al.  Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family. , 1997, The Journal of clinical investigation.

[10]  B. Yeung,et al.  Direct isoform analysis of high-mannose-containing glycoproteins by on-line capillary electrophoresis electrospray mass spectrometry. , 1997, Analytical chemistry.

[11]  V. Rosen,et al.  Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. , 1996, Biochemical and biophysical research communications.

[12]  T. Takagi,et al.  Calcification preceding new bone formation induced by demineralized bone matrix gelatin. , 1992, Archives of histology and cytology.

[13]  William Mendenhall,et al.  Introduction to Probability and Statistics , 1961, The Mathematical Gazette.

[14]  L. Teerenhovi.  Primary gastrointestinal lymphomas. , 1993, Annales chirurgiae et gynaecologiae.

[15]  T. Warner,et al.  Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant dnase in batch culture with increased sialic acid , 1998, Biotechnology and bioengineering.

[16]  V. Rosen,et al.  Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Hollinger,et al.  Sustained release emphasizing recombinant human bone morphogenetic protein-2. , 1998, Advanced drug delivery reviews.

[18]  J. Wozney,et al.  rhBMP‐Collagen Sponges as Osteoinductive Devices: Effects of in Vitro Sponge Characteristics and Protein pI on in Vivo rhBMP Pharmacokinetics , 1999, Annals of the New York Academy of Sciences.

[19]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988 .

[20]  T. Takagi,et al.  Ultrastructural observation of calcification preceding new bone formation induced by demineralized bone matrix gelatin. , 1992, Acta Anatomica.

[21]  M. Bostrom,et al.  Osseous regeneration in preclinical models using bioabsorbable delivery technology for recombinant human bone morphogenetic protein 2 (rhBMP-2) , 1995 .

[22]  W. Sebald,et al.  Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. , 1996, European journal of biochemistry.

[23]  A. Reddi,et al.  Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins. , 1997, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[24]  S D Cook,et al.  Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. , 1995, The Journal of bone and joint surgery. American volume.

[25]  J. Wozney,et al.  Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. , 1999, Journal of biomedical materials research.